Antcliff joined the firm’s dispute resolution team in 2016, having previously worked in-house at Actavis/Allergan, where she handled high-profile pregabalin and tadalafil litigations.
She has a scientific background, which includes a doctorate in molecular and structural biology from Oxford University.
During her career, she has represented clients in patent and supplementary protection certificate disputes centred on blockbuster small molecule drugs, therapeutic antibodies, enzyme replacement therapies, nanotechnology and orphan products at the UK Supreme Court and the Court of Justice of the European Union (CJEU).
“Jenny is an outstanding litigator and all the partners very much look forward to the future with Jenny in the team. Her promotion will further strengthen our integrated dispute resolution capability and the holistic, strategic service we provide for our clients,” said Hugh Goodfellow, managing partner at Carpmaels & Ransford.